Icecure Medical Ltd
ICCM0.675USD
+0.010+1.52%
收盘 12/19, 16:00（美东）报价延迟15分钟
46.54M总市值
亏损市盈率 TTM
关于 Icecure Medical Ltd 公司
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Icecure Medical Ltd简介
公司代码ICCM
公司名称Icecure Medical Ltd
上市日期Feb 02, 2011
CEOShamir (Eyal)
员工数量64
证券类型Ordinary Share
年结日Feb 02
公司地址7 Ha'eshel St.
城市CAESAREA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编3079504
电话97246230333
网址https://icecure-medical.com/
公司代码ICCM
上市日期Feb 02, 2011
CEOShamir (Eyal)
Icecure Medical Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--
Mr. Doron Birger
Mr. Doron Birger
Independent Director
Independent Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
External Director
External Director
--
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Chairman of the Board
Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Other
1.46M
44.24%
United States
870.00K
26.44%
Japan
481.00K
14.62%
India
413.00K
12.55%
China
41.00K
1.25%
Israel
30.00K
0.91%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
其他
60.47%
持股股东
持股股东
占比
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
其他
60.47%
股东类型
持股股东
占比
Individual Investor
40.42%
Investment Advisor
0.19%
Hedge Fund
0.13%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.02%
Venture Capital
0.02%
其他
59.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
33
241.02K
0.35%
-53.58K
2025Q2
45
28.04M
40.84%
+56.20K
2025Q1
44
28.01M
47.78%
-9.18K
2024Q4
41
27.61M
48.82%
+489.62K
2024Q3
42
27.95M
49.54%
-2.17M
2024Q2
41
27.48M
56.81%
+3.00M
2024Q1
39
27.22M
56.29%
+2.63M
2023Q4
40
21.73M
47.63%
-6.82M
2023Q3
37
21.68M
47.52%
-6.84M
2023Q2
36
21.65M
47.45%
-6.97M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Haixiang (Li)
25.85M
37.65%
--
--
Dec 31, 2024
Shamir (Eyal)
590.31K
0.86%
+69.67K
+13.38%
Mar 24, 2025
Tsimerman (Ronen)
355.08K
0.52%
+47.55K
+15.46%
Mar 24, 2025
Mayron (Ron)
278.02K
0.41%
+55.45K
+24.91%
Mar 24, 2025
Tel-Tzure (Tlalit Bussi)
191.81K
0.28%
+35.32K
+22.57%
Mar 24, 2025
Levav (Shay)
141.86K
0.21%
+37.69K
+36.18%
Mar 24, 2025
Muchnik (Naum)
140.42K
0.2%
+35.13K
+33.36%
Mar 24, 2025
Huang (Yang)
113.44K
0.17%
+40.12K
+54.72%
Mar 24, 2025
Dotan (Merav Nir)
88.94K
0.13%
+30.84K
+53.09%
Mar 24, 2025
Malik (Galit)
79.67K
0.12%
+23.32K
+41.40%
Mar 24, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Icecure Medical Ltd的前五大股东是谁？
Icecure Medical Ltd 的前五大股东如下：
Haixiang (Li)持有股份：25.85M，占总股份比例：37.65%。
Shamir (Eyal)持有股份：590.31K，占总股份比例：0.86%。
Tsimerman (Ronen)持有股份：355.08K，占总股份比例：0.52%。
Mayron (Ron)持有股份：278.02K，占总股份比例：0.41%。
Tel-Tzure (Tlalit Bussi)持有股份：191.81K，占总股份比例：0.28%。
Haixiang (Li)持有股份：25.85M，占总股份比例：37.65%。
Shamir (Eyal)持有股份：590.31K，占总股份比例：0.86%。
Tsimerman (Ronen)持有股份：355.08K，占总股份比例：0.52%。
Mayron (Ron)持有股份：278.02K，占总股份比例：0.41%。
Tel-Tzure (Tlalit Bussi)持有股份：191.81K，占总股份比例：0.28%。
Icecure Medical Ltd的前三大股东类型是什么？
Icecure Medical Ltd 的前三大股东类型分别是：
Haixiang (Li)
Shamir (Eyal)
Tsimerman (Ronen)
Haixiang (Li)
Shamir (Eyal)
Tsimerman (Ronen)
有多少机构持有Icecure Medical Ltd(ICCM)的股份？
截至2025Q3，共有33家机构持有Icecure Medical Ltd的股份，合计持有的股份价值约为241.02K，占公司总股份的0.35%。与2025Q2相比，机构持股有所增加，增幅为-40.49%。
哪个业务部门对Icecure Medical Ltd的收入贡献最大？
在FY2024，--业务部门对Icecure Medical Ltd的收入贡献最大，创收--，占总收入的--%。
